Dendritic Cell-Based Vaccine Targets HER2 with Promising Results

Overview of HER2 and Its Role in Cancer

A dendritic cell-based vaccine targeting the HER2 receptor has demonstrated significant potential in a phase-1 clinical trial. This research was presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. HER2 is a receptor located on the surfaces of certain cancer cells, where it binds to specific hormones and growth factors. This binding can trigger abnormal cell proliferation, resulting in aggressive cancer growth. Consequently, blocking HER2 is recognized as a beneficial strategy to inhibit the progression of cancers that express this receptor. Patients with this receptor on their cancer cells are categorized as HER2-positive.

Diagnostic Methods and Treatment Implications

Current diagnostic techniques are designed to identify patients as HER2-positive, enabling clinicians to provide targeted therapies while also determining which patients may not benefit from HER2-targeting treatments. The recent advancements in immunotherapy have empowered researchers to develop immune cells capable of recognizing these aberrantly expressed proteins.

Clinical Trial Findings

A notable breakthrough was shared at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held in New York from September 30 to October 3, 2018. Researchers from the Vaccine Branch at the Center for Cancer Research, National Cancer Institute in Maryland, engineered a class of immune cells from cancer patients using viral methods to express portions of HER2. These modified cells were then reinfused into the patients, effectively training the immune system to recognize and target HER2-expressing tumors.

Patient Responses and Outcomes

In an encouraging observation, one patient with ovarian cancer achieved a complete response lasting 89 weeks. Another patient with gastroesophageal cancer experienced a partial response for 16 weeks. Additionally, four patients with colon and prostate cancers showed no further progression of their cancer growth. The trial enrolled 11 patients, each receiving 10 to 20 million dendritic cells per injection at weeks 0, 4, 8, 16, and 24 post-enrollment. Among these, six patients reported documented clinical benefits, with no instances of cardiotoxicity and only mild adverse reactions.

Future Research Directions

The investigators expressed intentions to explore the combination of existing checkpoint immune therapies with the dendritic cell vaccine to evaluate if such combinations could enhance patient responses to treatment.

Source Information

This information was compiled by Vinayak Khattar, Ph.D., M.B.A. For more details, refer to the article “New cancer vaccine shows early promise for patients with HER2-positive cancers” available on EurekAlert!.